Following China vaccine sales overhaul, Sinovac posts dire Q2 results


While it wasn’t implicated in the illegal vaccine sales ring that rocked China earlier this year, Beijing-based Sinovac has surely felt the pain. In second-quarter results, the China-focused vaccine maker reported sales of $1.4 million versus $18.5 million during the same period last year.

It was the second straight quarter featuring a serious dropoff for the company after its sales slipped 50% in the first quarter, excluding H5N1 vaccine revenue. The cause? An overhaul of vaccine sales rules by Chinese regulators in response to an $88 million illegal vaccine sales ring uncovered earlier this year. 

Sinovac’s latest struggles amounted to a $2.4 million loss for the second quarter, compared to a $15.2 million profit during the period last year. The company will seek commercial loans to pay for product commercializations and operations, according to the earnings release.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Back in March, authorities discovered an illegal vaccine scheme led by a mother and daughter in Shandong that had been in operation for 5 years. The group was buying and selling vaccines outside of official channels and its exposure led to a nationwide crackdown on fake vaccines and a pledge to overhaul vaccine distribution.

“This impacted nationwide sales of private-pay market vaccines as vaccine companies halted vaccine delivery to wait for the interpretation of new regulation by the Chinese government,” Sinovac CEO Weidong Yin said in a statement.

But Sinovac execs are forecasting a “much stronger” second half, Yin said. In mid-June, regulators issued an interpretation of new regulations that allowed shipments to resume.

Big Pharmas with vaccine operations in China also were affected, with Sanofi ($SNY) execs saying last month that the company could take until the end of the year to overhaul its logistics system in response to the changes. GlaxoSmithKline ($GSK), which won the China FDA's first HPV vaccine approval in July, said it supports the moves.

Mostly focused on sales in China, Sinovac provides vaccines against hepatitis A and B, flu, mumps and Enterovirus 71, which causes hand, foot and mouth disease.

- here's the release

Related Articles:
Sinovac hit by new rules on vaccine sales in China
China plans vaccine distribution reforms after illegal sales scandal
China approves Sinovac's vaccine for hand, foot and mouth disease
Sanofi says China vaccine rules led to logistics overhaul
GSK wins China FDA's first HPV approval with Cervarix vaccine


Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.